Compare OFIX & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | MRVI |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 472.8M |
| IPO Year | 1998 | 2020 |
| Metric | OFIX | MRVI |
|---|---|---|
| Price | $12.72 | $3.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $17.25 | $4.13 |
| AVG Volume (30 Days) | 231.3K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | $185,743,000.00 |
| Revenue This Year | $6.10 | $12.44 |
| Revenue Next Year | $6.24 | $7.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $10.25 | $1.67 |
| 52 Week High | $16.99 | $4.11 |
| Indicator | OFIX | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 57.59 |
| Support Level | $12.33 | $3.25 |
| Resistance Level | $16.38 | $3.93 |
| Average True Range (ATR) | 0.41 | 0.16 |
| MACD | 0.19 | 0.04 |
| Stochastic Oscillator | 85.48 | 86.11 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.